Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing checkpoint modulator antibodies and cancer vaccines, today announced participation at the following conferences:
- The 6th Annual William Blair and Maidstone Life Sciences conference “Cancer Immunotherapy: A Long-Awaited Reality Conference” at the Apella, Event Space Alexandria Center in New York, NY on Thursday, March 31, 2016. Robert B. Stein, M.D., Ph.D., President, R&D will moderate three panels and present at a session titled “Integrated Approach to Optimizing Cancer Immunotherapy.”
- Cancer Advance Boston at Harvard Medical School – Joseph B. Martin Conference Center in Boston, MA on Monday, April 4, 2016. Dr. Stein will moderate a panel at 4:10 pm titled “Combination Therapy.”
- Jefferies Immuno-Oncology Summit at the Boston Harbor Hotel in Boston, MA on Thursday, April 7, 2016. Dr. Stein will present at 1:45 pm.
About Agenus
Agenus is an immuno-oncology company focused on
the discovery and development of revolutionary new treatments that
engage the body’s immune system to benefit patients suffering from
cancer. By combining multiple powerful platforms, Agenus has established
a highly integrated approach to target identification and validation,
and for the discovery, development and manufacturing of monoclonal
antibodies that modulate targets of interest. The company’s broad
portfolio of novel checkpoint modulator and other immuno-modulatory
monoclonal antibodies, vaccines and adjuvants, work in combination to
provide the opportunity to create best-in-class therapeutic regimens.
Agenus’ heat shock protein-based vaccine, Prophage™, has successfully
completed Phase 2 studies in newly-diagnosed glioblastoma. The company
is collaborating with Merck and Incyte to discover and develop multiple
checkpoint modulators. For more information, please visit www.agenusbio.com;
information that may be important to investors will be routinely posted
on our website.
Forward-Looking Statement
This press release contains
forward-looking statements that are made pursuant to the safe harbor
provisions of the federal securities laws, including statements
regarding the Company’s upcoming presentations. These forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially. These risks and uncertainties
include, among others, the factors described under the Risk Factors
section of Agenus’ Form 10-K filed with the Securities and Exchange
Commission on March 15, 2016. Agenus cautions investors not to place
considerable reliance on the forward-looking statements contained in
this release. These statements speak only as of the date of this press
release, and Agenus undertakes no obligation to update or revise the
statements, other than to the extent required by law. All
forward-looking statements are expressly qualified in their entirety by
this cautionary statement.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160330005310/en/
Contacts:
Michelle Linn, 781-674-4541
michelle.linn@agenusbio.com
or
Media:
BMC
Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com